Patents Issued in September 24, 2024
-
Patent number: 12097244Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.Type: GrantFiled: December 22, 2023Date of Patent: September 24, 2024Assignee: Altor BioScience, LLC.Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
-
Patent number: 12097245Abstract: A pharmaceutical composition having a hypoglycemic effect, comprising: a GLP-1 receptor agonist, and a composition for promoting small-intestinal absorption; wherein the composition for promoting small-intestinal absorption comprises sodium lauryl sulfate, carbomer, chitosan, and sodium citrate. The composition for promoting small intestinal absorption according to the present invention may be prepared into a composite adjuvant, which, when combined with a GLP-1 agonist, can improve the absorption of this active ingredient in the small intestine and the like.Type: GrantFiled: May 6, 2020Date of Patent: September 24, 2024Inventor: Jing Zhang
-
Patent number: 12097246Abstract: The invention is directed to a method of treating a spinal cord injury, a neurodegenerative disease or a neuronal injury in an individual in need thereof comprising administering an effective amount of superoxide dismutase (SOD) and catalase to the individual, wherein the superoxide dismutase and the catalase are encapsulated in one or more nanoparticles that release the SOD and catalase upon administration. Another aspect of the invention is directed to compositions comprising superoxide dismutase (SOD) and catalase encapsulated in one or more nanoparticles.Type: GrantFiled: June 22, 2022Date of Patent: September 24, 2024Assignee: The Cleveland Clinic FoundationInventors: Vinod Labhasetwar, Hayder H. Jaffer
-
Patent number: 12097247Abstract: The present invention relates to a pharmaceutical composition for treating gout and a gout treatment kit. According to an embodiment of the present invention, a pharmaceutical composition for treating gout comprising a probe containing at least one or more peptides specifically coupled to a monosodium urate (MSU) crystals and a first enzyme which is coupled to the probe and reacts with the target MSU crystal coupled to the probe or urea of surrounding joint fluid to remove the target MSU crystal is provided.Type: GrantFiled: August 18, 2020Date of Patent: September 24, 2024Assignee: UNIVERSITY-INDUSTRY FOUNDATION(UIF), YONSEI UNIVERSITYInventor: Jae-Chul Pyun
-
Patent number: 12097248Abstract: A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.Type: GrantFiled: October 22, 2021Date of Patent: September 24, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
-
Patent number: 12097249Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: January 21, 2022Date of Patent: September 24, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
-
Patent number: 12097250Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.Type: GrantFiled: November 9, 2023Date of Patent: September 24, 2024Assignee: Merck Sharp & Dohme LLCInventors: William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
-
Patent number: 12097251Abstract: Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.Type: GrantFiled: September 26, 2019Date of Patent: September 24, 2024Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Shaowei Li, Daning Wang, Jie Chen, Ying Gu, Jun Zhang, Ningshao Xia
-
Patent number: 12097252Abstract: The invention relates to a novel reconstitution composition, a pharmaceutical composition and kit of parts comprising said reconstitution composition. The invention further relates to a method of treatment using said pharmaceutical composition and/or the pharmaceutical composition for use as a medicament. Also provided is a method for reconstituting dried peptides and a method for preparing a pharmaceutical composition using the reconstitution composition of the invention.Type: GrantFiled: August 24, 2022Date of Patent: September 24, 2024Assignee: 1SA PHARMACEUTICALS B.V.Inventor: Gwenn Eveline Mulder
-
Patent number: 12097253Abstract: The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA suitable for use in treatment and/or prophylaxis of an infection with Respiratory syncytial virus (RSV) or a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial RNA, compositions and vaccines.Type: GrantFiled: February 28, 2024Date of Patent: September 24, 2024Assignee: CureVac SEInventors: Johannes Lutz, Susanne Rauch, Regina Heidenreich, Benjamin Petsch
-
Patent number: 12097254Abstract: The present disclosure provides a rabies composition comprising IPRV and PIKA adjuvant, and the pharmaceutical use thereof. The present disclosure also discloses a method for prophylaxis or therapeutic treatment of rabies virus infection, the method comprises a step of administering the rabies vaccine composition to a host. The rabies composition is more stable and safe, and is able to induce earlier and higher titers of neutralizing antibody.Type: GrantFiled: March 24, 2021Date of Patent: September 24, 2024Assignee: Yisheng Biopharma (Singapore) PTE LTDInventors: Lietao Li, Yi Zhang, Fang Liu
-
Patent number: 12097255Abstract: The present invention provides: a recombinant expression vector comprising a gene encoding a porcine parvovirus VP2 protein; a recombinant plant or a recombinant insect cell transformed with the vector; and a vaccine composition for a porcine parvovirus and a composition for diagnosing porcine parvovirus, both of which contain a porcine parvovirus VP2 protein obtained from the recombinant plant or the recombinant insect cell. When the recombinant plant or recombinant insect cell of the present invention is used, the porcine parvovirus antigenic protein can be produced with high efficiency, and the porcine parvovirus antigenic protein production method using the recombinant plant or recombinant insect cell has excellent safety and stability compared with other antigen production methods.Type: GrantFiled: November 15, 2019Date of Patent: September 24, 2024Assignees: REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY), BIOAPPLICATIONS INC.Inventors: Jae-Young Song, In-Ohk Ouh, Soodong Cho, Yongjik Lee, Ju-Yeon Lee, In-Soo Cho
-
Patent number: 12097256Abstract: Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound demonstrating enhanced stability, which in some embodiments comprises a protein and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for unrefrigerated storage for longer time periods than previous approaches, thus making feasible access to such products over a global supply chain.Type: GrantFiled: October 17, 2022Date of Patent: September 24, 2024Assignee: KBIO HOLDINGS LIMITEDInventors: Leigh Burden, Steven D. Hume, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, John W. Shepherd
-
Patent number: 12097257Abstract: Provided are polynucleotides and viral vectors, particularly, Alphavirus vectors such as Sindbis viral vectors, which encode an immune checkpoint protein, or a ligand binding portion of the checkpoint protein, or an immune checkpoint protein or ligand binding portion thereof fused to one or more immunoglobulin (Ig) domains, e.g., an Ig hinge region and an Ig heavy chain constant domain. Methods of treating a mammalian subject having a cancer or tumor are provided, in which the viral vectors, e.g., a Sindbis virus vector, encoding the immune checkpoint protein, a ligand binding portion thereof, or a checkpoint protein fusion protein as described, are administered to the subject, resulting in an anti-cancer or anti-tumor immune response, significant reduction in tumor growth in the treated subject and increased survivability.Type: GrantFiled: March 4, 2019Date of Patent: September 24, 2024Assignee: New York UniversityInventors: Daniel Meruelo, Alicia Hurtado Martinez, Christine Pampeno, Iris Scherwitzl
-
Patent number: 12097258Abstract: A Dectin-2 ligand vaccine adjuvant and a method of making and using the Dectin-2 ligand vaccine adjuvant in a vaccine to immunize a patient are disclosed. Also discloses is a vaccine composition comprising a Bl-Eng2 antigen and methods of using the vaccine composition to immunize a subject against a fungal infection.Type: GrantFiled: February 26, 2021Date of Patent: September 24, 2024Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Bruce Steven Klein, Huafeng Wang, Marcel Wuethrich, Tristan Theodore Brandhorst
-
Patent number: 12097259Abstract: The present disclosure provides a dendric cell tumor vaccine comprising a chimeric antigen receptor for activating the dendritic cell and a tumor antigen. The present disclosure also provides compositions and methods of making the dendritic cell tumor vaccine, and the methods of using the dendritic cell tumor vaccine to treat cancer.Type: GrantFiled: February 14, 2023Date of Patent: September 24, 2024Assignee: SHENZHEN FRONTIERGATE BIOTECHNOLOGY CO., LTDInventor: Yang Xu
-
Patent number: 12097260Abstract: A polymer composition can include an aqueous vehicle and a temperature-responsive degradable polymer having a polymer including a LCST-imparting unit and a lactone-bearing unit including a pendent lactone group. The number of LCST-imparting units is greater than the number of lactone-bearing units. The temperature-responsive degradable polymer has an initial lower critical solution temperature (LCST) of 37° C. or below. The polymer composition can have a pH lower than 7.Type: GrantFiled: November 16, 2021Date of Patent: September 24, 2024Assignee: Sonoran Biosciences, Inc.Inventor: Derek J. Overstreet
-
Patent number: 12097261Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: May 6, 2022Date of Patent: September 24, 2024Assignee: Kymera Therapeutics, Inc.Inventors: Xiaozhang Zheng, Yi Zhang, Robert Aversa, Xiao Zhu, Philip Collier
-
Patent number: 12097262Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.Type: GrantFiled: February 28, 2023Date of Patent: September 24, 2024Assignee: The Regents of the University of CaliforniaInventors: Kevan Shokat, Masanori Okaniwa
-
Patent number: 12097263Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.Type: GrantFiled: January 19, 2024Date of Patent: September 24, 2024Assignee: Dyne Therapeutics, Inc.Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins
-
Patent number: 12097264Abstract: Provided herein is a nanoparticle for drug delivery, wherein the nanoparticle comprises a hyperbranched polyester (HBPE) nanoparticle having a hydrophobic interior, polyglutamate folate ligands conjugated to the nanoparticle, and one or more PET detectable isotopes. Also provided herein are methods of using thereof.Type: GrantFiled: April 12, 2021Date of Patent: September 24, 2024Assignees: University of Central Florida Research Foundation, Inc., et al., Sanford Burnham Prebys Medical Discovery Institute at Lake Nona, , Memorial Sloan Kettering Cancer CenterInventors: Annette Khaled, Jesus Manuel Perez Figueroa, Santimukul Santra, Charalambos Kaittanis, Oscar Santiesteban, Jan Grimm, Hampton Sessions
-
Patent number: 12097265Abstract: The invention relates to cytotoxic particles for cancer therapy including a core and a plurality of variable domains arranged on the core for binding to P2X7 receptors on a cancer cell.Type: GrantFiled: January 13, 2022Date of Patent: September 24, 2024Assignee: BIOSCEPTRE (AUST) PTY LTDInventors: Xiaojuan Gong, Minoo J Moghaddam, Julian Alexander Barden
-
Patent number: 12097266Abstract: A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.Type: GrantFiled: November 17, 2023Date of Patent: September 24, 2024Assignee: Imam Abdulrahman Bin Faisal UniversityInventors: B. Rabindran Jermy, Vijaya Ravinayagam, Dana Almohazey
-
Patent number: 12097267Abstract: Codon optimized nucleic acid sequences for the long form and short form of RdCVF are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequences. Recombinant vectors are provided that express the codon optimized RdCVFL and RdCVF individually, or express two copies of a codon optimized RdCVF or RdCVFL nucleic acid sequence, or both RdCVFL and RdCVF in a single vector or virus. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence or inappropriate expression of RdCVF and RdCVFL.Type: GrantFiled: November 16, 2020Date of Patent: September 24, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Jeannette Bennicelli, Jean Bennett, Junwei Sun
-
Patent number: 12097268Abstract: Provided herein are compositions and methods for the design of synthetic regulatory sequences and for subsequent modulation of neural pathways.Type: GrantFiled: March 19, 2020Date of Patent: September 24, 2024Assignee: EOS Neuroscience, Inc.Inventors: Alan Horsager, Andrew Smith, Benjamin C. Matteo
-
Patent number: 12097269Abstract: Provided herein are nanoparticle-based gadolinium (Gd) agents which may be used, e.g., in T1-weighted MR imaging (MRI). In various embodiments, dual-Gd liposomal agents are provided which contain both core-encapsulated Gd as well as surface-conjugated Gd. In various embodiments, these agents were observed to deliver a higher concentrations of Gd and result in substantial improvements in signal to noise ratios and contrast to noise ratios. Also provided are methods for in vivo imaging and/or treating diseases such as cancer or tumor in a subject.Type: GrantFiled: October 27, 2011Date of Patent: September 24, 2024Inventors: Vikas Kundra, James A. Bankson, Ananth Annapragada, Ketan B. Ghaghada, Murali K. Ravoori
-
Patent number: 12097270Abstract: Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.Type: GrantFiled: February 3, 2020Date of Patent: September 24, 2024Assignee: Lantheus Medical Imaging, Inc.Inventors: Simon P. Robinson, Carol Walker, David C. Onthank, Joel Lazewatsky, Nhung Tuyet Nguyen
-
Patent number: 12097271Abstract: Dental root canal filling composition comprising (a) one or more diepoxides; (b) one or more primary monoamines and/or disecondary diamines; (c) a particulate filler, wherein the one or more diepoxides are selected from compounds of the following formula (I) or a salt thereof:Type: GrantFiled: April 9, 2020Date of Patent: September 24, 2024Assignee: DENTSPLY SIRONA INC.Inventors: Joachim E. Klee, Matthias Worm
-
Patent number: 12097272Abstract: An ultraviolet protection patch is provided. An ultraviolet protection patch, according to one embodiment of the present invention, is implemented by comprising: an ultraviolet protection layer including a support component and an ultraviolet protection agent; and a first shape-retaining layer which is a fiber web provided on one surface of the ultraviolet protection layer.Type: GrantFiled: November 8, 2019Date of Patent: September 24, 2024Assignee: AMOLIFESCIENCE CO., LTD.Inventors: Su Yeon Lee, Ji Young Kim, Hyo Jung Lee, In Yong Seo, Seoung Hoon Lee
-
Patent number: 12097273Abstract: Disclosed is a method of treating skin with a composition comprising an extract from Magnolia officinalis.Type: GrantFiled: April 18, 2023Date of Patent: September 24, 2024Assignee: MARY KAY INC.Inventors: Jim Faller, David Gan, Michelle Hines, Lisa Mangos
-
Patent number: 12097274Abstract: The subject of the present application is an agent for the oxidative dyeing of keratinous fibers, in particular human hair, which contains the coupling oxidation dye precursor 2-(1,3-benzodioxol-5-ylamino)ethanol in combination with the oxidation base 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole.Type: GrantFiled: February 17, 2023Date of Patent: September 24, 2024Assignee: Henkel AG & Co. KGaAInventors: Razi Abbas, Tugce Cansev, Thomas Hippe, Astrid Kleen, Hartmut Manneck, Stefan Hoepfner, Tiffany Lea Fielder
-
Patent number: 12097275Abstract: A hair coloring method may include a step of applying a mixture of the following (A) and (B) in a predetermined ratio: (A) a hair coloring agent comprising at least a basic dye, a HC dye, a second amino acid, a first cationic surfactant, a thickener, an oil agent, a first pH adjusting agent, a wetting agent and at least one selected from the group consisting of thioglycolic acid, cysteine, 3-mercapto-1,2-propanediol, cysteamine, and derivatives and salts thereof, wherein the pH of the hair coloring agent is pH 3.5 or higher, and (B) a hair cosmetics comprising at least an alkaline agent, a first amino acid, higher alcohols having 12 to 22 carbon atoms, a surfactant, and a thickener. The hair coloring method may further include a step of providing a predetermined time after the application.Type: GrantFiled: December 18, 2018Date of Patent: September 24, 2024Assignee: SUNNYPLACE CO., LTD.Inventors: Nobuhito Mukai, Takashi Mukai
-
Patent number: 12097276Abstract: A composition contains, as an effective component, theasinensin A, an enantiomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The composition has an excellent stability and provides wrinkle-reducing or skin elasticity-enhancing benefits, and skin-brightening benefits by containing theasinensin A, an enantiomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, as an effective component.Type: GrantFiled: November 6, 2019Date of Patent: September 24, 2024Assignees: AMOREPACIFIC CORPORATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Eun Mi Kim, Kyeonghwan Hwang, Dong Hyun Kim, Byung-Gee Kim, Jinkyung Choi
-
Patent number: 12097277Abstract: A sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 ?mol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 ?mol per gram polymer, wherein the composition has a residual thiol content of less than 20% in respect to the degree of modification of the thiol-modified hyaluronan.Type: GrantFiled: June 14, 2019Date of Patent: September 24, 2024Assignee: CROMA-PHARMA GMBHInventors: Martin Prinz, Ralph Hollaus, Robert Sachsenhofer
-
Patent number: 12097278Abstract: Film forming compositions and methods for preventing stains and increasing shine and gloss of teeth. The film forming compositions may include a polymer, such as a hydrophobic polymer, and an orally acceptable solvent. The hydrophobic polymer may include an acrylate component and a hydrophobic group coupled with one another. The hydrophobic group may include an alkyl chain, a polyethylene glycol, a polypropylene, a polyester, a polyorthoester, a phospholipid, a long chain fatty acid, a vinyl chloride, fluorethylene, a siloxane, a urethane, an octylacrylamide, a butylaminoethyl, a styrene, and combinations thereof.Type: GrantFiled: February 28, 2022Date of Patent: September 24, 2024Assignee: Colgate-Palmolive CompanyInventors: Michael North, Rong Dong, Paloma Pimenta, Shira Pilch
-
Patent number: 12097279Abstract: A particular composition of the present disclosure is designed to work as a topical composition. The composition relies on a unique combination of any one of, any combination of, or all of Brassica campestris (rapeseed) sterols, Rhododendron ferrugineum extract, Oenothera biennis (evening primrose) oil, and a combination of peptides and polypeptides. The compositions are useful for moisturizing and conditioning the skin.Type: GrantFiled: September 18, 2018Date of Patent: September 24, 2024Assignee: MARY KAY INC.Inventors: Patricia Jacoby, David Gan, Geetha Kalahasti
-
Patent number: 12097280Abstract: Personal care compositions and methods for treating one or more dry skin conditions are disclosed. The composition may include a carrier, one or more plant oils, and a source of Aloe vera. The one or more plant oils and the source of Aloe vera may each be present in an effective amount to increase natural moisturizing factors in skin when applied thereto. The method for treating the one or more dry skin conditions may include contacting the personal care composition with skin. Contacting the personal care composition with the skin may increase an amount of natural moisturizing factors in the skin and/or increase an amount of Caspase-14 in the skin.Type: GrantFiled: December 2, 2020Date of Patent: September 24, 2024Assignee: Colgate-Palmolive CompanyInventors: Qiang Wu, Laurence Du-Thumm, Shujiang Cheng, Adriana Armas, Luis Miguel Lopez, Alejandro Meneses
-
Patent number: 12097281Abstract: A composition for improving skin moisturization of companion animals, including 10 to 20 parts by weight (“wt. parts”) of olive oil, 5 to 10 wt. parts of oleanolic acid acetate powder, 30 to 40 wt. parts of barley sprout fermented extract powder, 30 to 40 wt. parts of broccoli sprout fermented extract powder, 5 to 15 wt. parts of coconut extract fine powder, 1.5 to 2.5 wt. parts of sodium hyaluronate purified powder, 5.5 to 10 wt. parts of trehalose powder, 5 to 10 wt. parts of chlorella powder, and 5 to 10 wt. parts of green leaf mussel extract powder, based on 100 wt. parts of purified water.Type: GrantFiled: April 9, 2024Date of Patent: September 24, 2024Inventor: Tae Yoon Kim
-
Patent number: 12097282Abstract: A method for treating vascular diseases is provided. The method includes fabricating a sterile ice slurry including water and ice particles, cooling the sterile ice slurry to a predetermined temperature, and injecting the sterile ice slurry into a desired tissue region. The desired tissue region includes perivascular adipose tissue.Type: GrantFiled: October 14, 2022Date of Patent: September 24, 2024Assignee: The General Hospital CorporationInventors: Lilit Garibyan, William A. Farinelli, Richard Rox Anderson, Emilia Javorsky
-
Patent number: 12097283Abstract: Disclosed herein is a method for alleviating dry eye syndrome using a composition containing a polylysine nanoparticle. The polylysine nanoparticle is produced by subjecting lysine hydrochloride to a pyrolysis treatment at a temperature ranging from 240° C. to 280° C.Type: GrantFiled: September 19, 2022Date of Patent: September 24, 2024Assignees: Chang Gung University, Giant Bio Technology Inc.Inventors: Jui-Yang Lai, Chih-Ching Huang, Han-Jia Lin, Hong-Jyuan Jian
-
Patent number: 12097284Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: February 15, 2024Date of Patent: September 24, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Patent number: 12097285Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: February 15, 2024Date of Patent: September 24, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Patent number: 12097286Abstract: A confectionery method includes dissolving at least one active ingredient in a volatile vehicle to form a solution, applying the solution to a substrate and evaporating the volatile vehicle to leave the at least one active ingredient applied to the substrate. A confection includes an edible substrate and at least one active ingredient provided to the edible substrate.Type: GrantFiled: January 4, 2024Date of Patent: September 24, 2024Inventors: Erik Lawrence Kreider, Bryan E. Burke
-
Patent number: 12097287Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.Type: GrantFiled: January 12, 2024Date of Patent: September 24, 2024Assignee: BELHAVEN BIOPHARMA INC.Inventors: Scott Lyman, Barry Bleske, Ted William Lanpher
-
Patent number: 12097288Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.Type: GrantFiled: June 3, 2022Date of Patent: September 24, 2024Assignee: Cristcot LLCInventor: Jennifer J. Davagian
-
Patent number: 12097289Abstract: The disclosure provides stable formulations of cationic biocides that are primarily used in the treatment and prevention of infections. The disclosure is also concerned with processes for forming stable emulsions of cationic biocides and petrolatum.Type: GrantFiled: December 28, 2020Date of Patent: September 24, 2024Assignee: GLOBAL HEALTH SOLUTIONS LLCInventor: Bradley Burnam
-
Patent number: 12097290Abstract: Provided are nanoparticles and methods of using and making thereof. The inventive nanoparticle comprises a) an inner core comprising a non-cellular material; and b) an outer surface comprising a cellular membrane derived from a cell or a membrane derived from a virus. Medicament delivery systems or pharmaceutical compositions comprising the inventive nanoparticles are also provided. Further provided are immunogenic compositions comprising the inventive nanoparticles, and methods of using the inventive immunogenic compositions for eliciting an immune response, and for treating or preventing diseases or condition, such as neoplasm or cancer, or disease or conditions associated with cell membrane inserting toxin. Vaccines comprising the immunogenic composition comprising the nanoparticles are also provided.Type: GrantFiled: March 14, 2013Date of Patent: September 24, 2024Assignee: The Regents of the University of CaliforniaInventors: Liangfang Zhang, Che-Ming (Jack) Hu, Ronnie Hongbo Fang, Jonathan Copp
-
Patent number: 12097291Abstract: Compositions relating to thermostable vaccines and methods of preparing the same. Specifically, methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject.Type: GrantFiled: May 10, 2021Date of Patent: September 24, 2024Assignees: The Regents of the University of Colorado, a body corporate, Soligenix, Inc.Inventors: Kimberly Hassett, Pradyot Nandi, Robert N. Brey, John Carpenter, Theodore Randolph
-
Patent number: 12097292Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.Type: GrantFiled: September 2, 2022Date of Patent: September 24, 2024Assignee: MAPI PHARMA LTD.Inventors: Nadav Bleich Kimelman, Shai Rubnov, Ehud Marom
-
Patent number: 12097293Abstract: Provided is a transdermal drug delivery system comprising cannabidiol, or a cannabidiol salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.Type: GrantFiled: October 13, 2020Date of Patent: September 24, 2024Assignee: Pike Therapeutics Inc.Inventors: Fotios M. Plakogiannis, Tamanna Lather, Nisarg Modi, Marina Borovinskaya